biphasic insulin aspart (Novo Nordisk)

Biphasic insulin aspart is a premixed, fixed-ratio combination of two human insulin analogs: **insulin aspart** (a rapid-acting analog) and **insulin aspart protamine** (an intermediate-acting analog). The mixture typically consists of 30% soluble insulin aspart and 70% protamine-crystallized insulin aspart. This formulation is designed to mimic the physiological biphasic insulin secretion of the pancreas, providing both a rapid onset of action (within 10–20 minutes) to control postprandial glucose spikes and a prolonged duration of action (up to 24 hours) for basal glycemic control. It is administered via subcutaneous injection and is primarily indicated for improving glycemic control in adults with type 1 or type 2 diabetes mellitus. The drug was developed and is manufactured by **Novo Nordisk**.

Brand names

NovoLOG Mix 70/30NovoMix 30NovoMix30NovoMix-30NovoMix 50NovoMix50NovoMix-50NovoMix 70NovoMix70NovoMix-70

Other names

insulin aspart + protamine insulin aspartinsulin aspart 30/70insulin aspart protamine and insulin aspartpremixed insulin aspart